0001104659-22-023770.txt : 20220215
0001104659-22-023770.hdr.sgml : 20220215
20220215160148
ACCESSION NUMBER: 0001104659-22-023770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210716
FILED AS OF DATE: 20220215
DATE AS OF CHANGE: 20220215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Altarac David
CENTRAL INDEX KEY: 0001792615
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38670
FILM NUMBER: 22639126
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc.
CENTRAL INDEX KEY: 0001724344
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824592913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 810-0120
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Entasis Therapeutics Ltd
DATE OF NAME CHANGE: 20171204
4
1
tm226724d3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-07-16
0
0001724344
Entasis Therapeutics Holdings Inc.
ETTX
0001792615
Altarac David
C/O ENTASIS THERAPEUTICS HOLDINGS INC.,
35 GATEHOUSE DRIVE
WALTHAM
MA
02451
0
1
0
0
Chief Medical Officer
Employee Stock Option (Right to Buy)
5.70
2021-07-16
4
D
0
120000
D
2029-11-03
Common Stock
120000
0
D
Employee Stock Option (Right to Buy)
2.44
2021-07-16
4
A
0
92.307
A
2031-07-15
Common Stock
92307
92307
D
The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on November 4, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 120,000 shares of issuer's common stock granted to the Reporting Person on November 4, 2019. In exchange, the Reporting Person received a replacement option for 92,307 shares of issuer's common stock, having an exercise price of $2.44 per share.
Sixty-seven percent (67%) of this award will vest on July 16, 2022, and one-sixteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
Elizabeth M. Keiley as Attorney-in-Fact for David Altarac
2022-02-14